Safety constiderations in the use of intraoperative intraperitoneal chemotherapy

  • Susan K. White
  • Arvil D. Stephens
  • Barbara Dowjat
  • Paul H. Sugarbaker
Part of the Cancer Treatment and Research book series (CTAR, volume 82)

Abstract

The drugs frequently used intraoperatively within the abdomen and pelvis at the present time are cisplatin and mitomycin C. Both of these drugs are used at 43°C for 1–2 hours at maximal systemic doses of the drugs. The major toxicity of these drugs is renal impairment, which can be minimized by maintenance of a brisk diuresis, thus protecting all patients with normal renal function. In our experience with these renal toxic drugs, the safest place for their administration is the operating room. Monitoring the urine output at 15 minute intervals should eliminate drug pooling in the kidney tubules and consequent renal tubular insult. Large volumes of fluid can be safely used without fear of pulmonary edema because patients are endotracheally intubated and on positive pressure ventilation. Renal dopamine at 3μg/kg/min is regularly used in order to promote a diuresis. If urine output falls below 100 ml every 15 minutes, then a diuretic is given as an intravenous bolus. Generally furosemide administered at 10–20mg will result in more than a liter of urine in only a few minutes time.

Keywords

Operating Room Peritoneal Carcinomatosis Intraperitoneal Chemotherapy Infusion Catheter Renal Dopamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Maeta M, Hamazoe R, Koga S. Biological and clinical effects of whole-body hyperthermia for patients with disseminated malignancy. In Matsuda T, ed. Cancer Treatment by Hyperthermia, Radiation and Drugs. Bistol, PA: Tayor & Francis, 1993, pp 366–375.Google Scholar
  2. 2.
    Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N, Takamizawa H. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Fernandez-Trigo U, Stuart OA, Stephens AD, Hoover LD, Sugarbaker PH. Surgically directed chemotherapy: Heated intraperitoneal lavage with mitomycin C. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Drugs and Diseases. Norwell, MA: Kluwer Academic Publishers, 1996, pp 51–61.CrossRefGoogle Scholar
  4. 4.
    Stephens AD, Belliveau JF, Sugarbaker PH. Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and Sarcomatosis. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Diagnosis and Management. Norwell, MA: Kluwer Academic, 1995, pp 15–30.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1996

Authors and Affiliations

  • Susan K. White
  • Arvil D. Stephens
  • Barbara Dowjat
  • Paul H. Sugarbaker

There are no affiliations available

Personalised recommendations